KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Bionano Genomics (BNGO) Shares Outstanding (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Shares Outstanding for 9 consecutive years, with $10.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 475.76% to $10.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Dec 2025, up 475.76% year-over-year, with the annual reading at $10.7 million for FY2025, 475.76% up from the prior year.
  • Shares Outstanding hit $10.7 million in Q4 2025 for Bionano Genomics, up from $9.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $289.7 million in Q1 2022 to a low of $495300.0 in Q4 2022.
  • Historically, Shares Outstanding has averaged $67.5 million across 5 years, with a median of $19.9 million in 2021.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 638.49% in 2021 and later tumbled 98.29% in 2022.
  • Year by year, Shares Outstanding stood at $29.0 million in 2021, then crashed by 98.29% to $495300.0 in 2022, then surged by 53.97% to $762600.0 in 2023, then surged by 144.61% to $1.9 million in 2024, then soared by 475.76% to $10.7 million in 2025.
  • Business Quant data shows Shares Outstanding for BNGO at $10.7 million in Q4 2025, $9.7 million in Q3 2025, and $3.9 million in Q2 2025.